Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation

EBioMedicine. 2024 Apr:102:105088. doi: 10.1016/j.ebiom.2024.105088. Epub 2024 Mar 26.

Abstract

Metabolic dysfunction-associated steatohepatitis (MASH) is characterised by cell death of parenchymal liver cells which interact with their microenvironment to drive disease activity and liver fibrosis. The identification of the major death type could pave the way towards pharmacotherapy for MASH. To date, increasing evidence suggest a type of regulated cell death, named ferroptosis, which occurs through iron-catalysed peroxidation of polyunsaturated fatty acids (PUFA) in membrane phospholipids. Lipid peroxidation enjoys renewed interest in the light of ferroptosis, as druggable target in MASH. This review recapitulates the molecular mechanisms of ferroptosis in liver physiology, evidence for ferroptosis in human MASH and critically appraises the results of ferroptosis targeting in preclinical MASH models. Rewiring of redox, iron and PUFA metabolism in MASH creates a proferroptotic environment involved in MASH-related hepatocellular carcinoma (HCC) development. Ferroptosis induction might be a promising novel approach to eradicate HCC, while its inhibition might ameliorate MASH disease progression.

Keywords: Ferroptosis; Glutathione peroxidase; Hepatocellular carcinoma; Labile iron; Lipid hydroperoxides; Lipid peroxidation; Metabolic dysfunction-associated steatohepatitis; Phospholipids; Polyunsaturated fatty acids.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular* / pathology
  • Fatty Liver* / etiology
  • Ferroptosis*
  • Humans
  • Iron / metabolism
  • Lipid Peroxidation
  • Liver Neoplasms* / pathology
  • Tumor Microenvironment

Substances

  • Iron